Base documentaire
-
Pharmacokinetic dosing in prophylactic treatment of hemophilia A.
EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 51, n° 4, 1993, pages 247-252, 13 réf., ISSN 0902-4441, DNK
CARLSSON (M.), BERNTORP (E.), BJORKMAN (S.), LINDVALL (K.)
Malmö gen hosp. Hosp pharmacy. Malmö. SWE
The aim of this study was to investigate individual pharmacokinetics as a tool for dosing of factor VIII (FVIII) in severe hemophilia A. It is assumed that effective prophylaxis against bleedings is maintained if the plasma FVIII:C activity is kept above 1 U/dl, and the present study is based on this assumption.
A current standard dosage regimen for FVIII is 25-40 U/kg up to three times weekly.
However, there is considerable individual variation in the pharmacokinetics of FVIII:C. Individual pharmacokinetic data were used to computer-simulate plasma activity curves after repeated doses in 8 patients.
Mots-clés BDSP : Pharmacocinétique, Dérivé sanguin, Prévention, Analyse coût efficacité, Economie santé, Suède, Europe, Homme, Hémopathie, Maladie héréditaire, Thérapeutique
Mots-clés Pascal : Hémophilie A, Pharmacocinétique, Dosage, Facteur antihémophilique A, Constituant sang, Prévention, Transfusion, Analyse coût efficacité, Economie santé, Suède, Europe, Homme, Hémopathie, Coagulopathie, Maladie héréditaire, Facteur coagulation, Traitement
Mots-clés Pascal anglais : Hemophilia A, Pharmacokinetics, Assay, Factor VIII, Blood product, Prevention, Transfusion, Cost efficiency analysis, Health economy, Sweden, Europe, Human, Hemopathy, Coagulopathy, Genetic disease, Coagulation factor, Treatment
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et TechniqueCote : 94-0083053
Code Inist : 002B27D01. Création : 199406.
Banque de données en santé publique - http://www.bdsp.ehesp.fr/